STOCK TITAN

Oncternal Therapeutics, Inc. - ONCT STOCK NEWS

Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.

One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.

Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.

Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.

Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provided a business update and reported third quarter 2023 financial results. They announced the dosing of the first patient in the Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer treatment. They also treated additional patients in the ongoing Phase 1/2 study for ONCT-808, an autologous CAR T cell therapy, for aggressive B-cell lymphoma. The company has $40.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023, with a cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report Q3 2023 financial results on November 9, 2023, after the U.S. financial markets close. The management will host a webcast at 2:00 p.m. PT to provide a business update and discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics receives Fast Track designation from FDA for ONCT-534 in the treatment of mCRPC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
Rhea-AI Summary
Oncternal Therapeutics adds Dr. Matthew Smith to its Prostate Cancer Scientific Advisory Board to guide the clinical development of ONCT-534, a dual-acting androgen receptor inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management
-
Rhea-AI Summary
Oncternal Therapeutics announces dosing of first patient in Phase 1/2 study of ONCT-534
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Oncternal Therapeutics establishes Prostate Cancer Scientific Advisory Board (SAB) to support the development of its dual-acting androgen receptor inhibitor, ONCT-534. Members of the SAB include world-renowned leaders in prostate cancer research. This development could positively impact the company's stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
management
Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, has obtained FDA IND clearance for ONCT-534, a dual-action androgen receptor inhibitor for the treatment of advanced prostate cancer. They have also dosed the first patient in their Phase 1/2 study for ONCT-808, a ROR1-targeting autologous CAR T cell therapy for aggressive B-cell lymphoma. The company has extended its cash runway into 2025 with $45.5 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) to Report Q2 2023 Financial Results and Host Webcast for Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics receives FDA authorization for Phase 1/2 study of ONCT-534 in metastatic castration-resistant prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none

FAQ

What is the current stock price of Oncternal Therapeutics (ONCT)?

The current stock price of Oncternal Therapeutics (ONCT) is $0.5266 as of December 4, 2024.

What is the market cap of Oncternal Therapeutics (ONCT)?

The market cap of Oncternal Therapeutics (ONCT) is approximately 1.6M.

What does Oncternal Therapeutics specialize in?

Oncternal Therapeutics specializes in developing novel oncology therapies targeting cancers with significant unmet medical needs.

What are the key products in Oncternal's pipeline?

Key products include zilovertamab, ONCT-216, ONCT-808, and ONCT-534, targeting various malignancies and currently in different phases of clinical trials.

What is zilovertamab?

Zilovertamab is a humanized monoclonal antibody targeting ROR1, in Phase 1/2 trials for mantle cell lymphoma, chronic lymphocytic leukemia, and HER2-negative metastatic breast cancer.

What is ONCT-534?

ONCT-534 is a dual-action androgen receptor inhibitor in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms in relapsed patients.

How is Oncternal funded?

Oncternal has solid operational funding supporting its ongoing clinical trials, with strategic partnerships and collaborations fostering innovation.

What makes ONCT-808 unique?

ONCT-808 is a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors.

What is the significance of ONCT-216?

ONCT-216 is a small molecule inhibitor of ETS-family oncoproteins, currently in Phase 1 trials to treat Ewing sarcoma and other potential indications.

What are the current clinical trials for Oncternal's products?

Ongoing trials include zilovertamab in Phase 1/2 for lymphoma and breast cancer, ONCT-534 in Phase 1/2 for prostate cancer, ONCT-808 in preclinical models, and ONCT-216 in Phase 1 for Ewing sarcoma.

Where can I find more information about Oncternal Therapeutics?

More information about Oncternal Therapeutics and its programs can be found on their official website at https://oncternal.com/.

How does Oncternal aim to address unmet medical needs?

Oncternal aims to address unmet medical needs by developing innovative therapies that target promising, yet untapped biological pathways implicated in cancer generation or progression.

Oncternal Therapeutics, Inc.

Nasdaq:ONCT

ONCT Rankings

ONCT Stock Data

1.56M
2.68M
9.23%
12.07%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO